These results illustrated that the therapeutic effects of Tau + wsTP or Tau + lsTP treatment on NASH rats were superior to those of taurine or TPs (wsTP or lsTP) treatment alone (Fig. 2a and b). The gene discussed is MAPT; the disease is metabolic dysfunction-associated steatohepatitis.